$TESI
Titan Environmental Solutions Inc Stock $tesi

$tesi Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000149315224019697 Filed on May 15, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q4
Revenue	$2.661M	$1.756M	$2.056M
YoY Change	1344.92%	2599.49%	130049.37%
Cost Of Revenue	$2.103M	$1.623M	$1.799M
YoY Change	36.19%	4261.45%	3219.22%
Gross Profit	$558.2K	$132.6K	$257.0K
YoY Change	552.21%	376.55%	-588.33%
Gross Profit Margin	20.98%	7.55%	12.5%
Selling, General & Admin		$1.762M	$1.949M
YoY Change		459.05%	49.18%
% of Gross Profit		1328.95%	758.52%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$193.8K	$192.9K	$147.9K
YoY Change	-19.79%	-52.93%	546.7%
% of Gross Profit	34.73%	145.46%	57.55%
Operating Expenses	$2.334M	$1.955M	$1.780M
YoY Change	-67.91%	169.66%	32.83%
Operating Profit	-$1.775M	-$1.822M	-$1.523M
YoY Change	-74.59%	161.4%	9.36%
Interest Expense	$3.304K	-$493.0K	-$695.0K
YoY Change	-100.95%	-99.56%	-74.84%
% of Operating Profit
Other Income/Expense, Net	-$578.6K	-$436.6K	-$28.26K
YoY Change	-96.36%	-99.61%
Pretax Income	-$2.354M	-$2.259M	-$6.849M
YoY Change	-89.72%	-97.98%	185.16%
Income Tax
% Of Pretax Income
Net Earnings	-$2.354M	-$2.259M	-$7.924M
YoY Change	-89.72%	-97.98%	-13.6%
Net Earnings / Revenue	-88.46%	-128.66%	-385.35%
Basic Earnings Per Share	-$0.03	-$0.01
Diluted Earnings Per Share	-$0.03	-$0.01	-$0.52
COMMON SHARES
Basic Shares Outstanding	25.39M shares	25.39M shares	15.13M shares
Diluted Shares Outstanding	222.1M shares	222.1M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments		$3.430K	$103.6K
YoY Change		-97.54%	7806.87%
Cash & Equivalents	$56.79K	$3.427K	$103.6K
Short-Term Investments
Other Short-Term Assets		$219.0K	$248.9K
YoY Change		1885.13%	447.89%
Inventory	$504.9K	$219.9K	$145.0K
Prepaid Expenses
Receivables	$2.087M	$934.9K	$970.6K
Other Receivables		$0.00	$7.350K
Total Short-Term Assets	$2.806M	$1.377M	$1.475M
YoY Change	57.33%	138.96%	2120.12%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.57M	$6.403M	$5.781M
YoY Change	105.69%	553778.63%
Goodwill	$20.38M	$6.517M	$6.517M
YoY Change	206.47%	-10.64%
Intangibles	$6.270M	$6.462M	$6.654M
YoY Change	-43.98%	-38.14%
Long-Term Investments
YoY Change
Other Assets	$15.67K	$668.2K	$165.7K
YoY Change	89.89%
Total Long-Term Assets	$38.80M	$21.53M	$20.70M
YoY Change	53.99%	21.36%
TOTAL ASSETS
Total Short-Term Assets	$2.806M	$1.377M	$1.475M
Total Long-Term Assets	$38.80M	$21.53M	$20.70M
Total Assets	$41.60M	$22.91M	$22.18M
YoY Change	54.21%	25.06%	33266.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$4.364M	$3.476M
YoY Change		368.04%	1436.64%
Accrued Expenses		$1.258M	$979.5K
YoY Change		959.48%	3944.3%
Deferred Revenue
YoY Change
Short-Term Debt		$2.984M	$2.872M
YoY Change
Long-Term Debt Due	$5.435M	$4.420M	$3.911M
YoY Change		22.51%	420.22%
Total Short-Term Liabilities	$17.87M	$14.50M	$12.41M
YoY Change	64.1%	-87.66%	637.56%
LONG-TERM LIABILITIES
Long-Term Debt	$6.169M	$3.281M	$3.175M
YoY Change
Other Long-Term Liabilities		$1.200M	$1.291M
YoY Change
Total Long-Term Liabilities	$6.836M	$4.717M	$4.466M
YoY Change	71.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.87M	$14.50M	$12.41M
Total Long-Term Liabilities	$6.836M	$4.717M	$4.466M
Total Liabilities	$24.71M	$19.22M	$16.88M
YoY Change	66.18%	-83.64%	902.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$155.6M	-$153.2M	-$150.1M
YoY Change	560.01%	18.41%	756.49%
Common Stock	$2.539K	$2.539K	$1.513K
YoY Change	-25.87%	-25.19%	-16.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.996M	$3.690M	$5.299M
YoY Change
Total Liabilities & Shareholders Equity	$41.60M	$22.91M	$22.18M
YoY Change	54.21%	25.06%	33266.65%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q4
OPERATING ACTIVITIES
Net Income	-$2.354M	-$2.259M	-$7.924M
YoY Change	-89.72%	-97.98%	-13.6%
Depreciation, Depletion And Amortization	$193.8K	$192.9K	$147.9K
YoY Change	-19.79%	-52.93%	546.7%
Cash From Operating Activities		-$822.5K	-$1.095M
YoY Change		327.38%	162.71%
INVESTING ACTIVITIES
Capital Expenditures		$734.9K	$483.8K
YoY Change			151093.75%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities		-$734.9K	-$483.8K
YoY Change		389.95%	151093.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		$1.457M	1.084M
YoY Change		203.15%	332.06%
NET CHANGE
Cash From Operating Activities		-$822.5K	-1.095M
Cash From Investing Activities		-$734.9K	-483.8K
Cash From Financing Activities		$1.457M	1.084M
Net Change In Cash		-$100.2K	-494.8K
YoY Change		-172.44%	197.63%
FREE CASH FLOW
Cash From Operating Activities		-$822.5K	-$1.095M
Capital Expenditures		$734.9K	$483.8K
Free Cash Flow		-$1.557M	-$1.579M
YoY Change		709.27%	278.49%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4716506	usd
CY2024Q1	us-gaap	Liabilities Liabilities	19217412	usd
CY2024Q1	us-gaap	Other Receivables OtherReceivables		usd
CY2024Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	TESI	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability		usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		usd
CY2024Q1	TESI	Stock Issued During Period Value Exercise Of Share Prefunded Warrants StockIssuedDuringPeriodValueExerciseOfSharePrefundedWarrants		usd
CY2023Q1	us-gaap	Provision For Loan Lease And Other Losses ProvisionForLoanLeaseAndOtherLosses		usd
CY2023Q1	TESI	Change In Fair Value Of Derivative Liability And Derivative Expense ChangeInFairValueOfDerivativeLiabilityAndDerivativeExpense		usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets		usd
CY2023Q1	TESI	Increase Decrease In Deposit IncreaseDecreaseInDeposit		usd
CY2024Q1	TESI	Proceeds From Subscription Receivable ProceedsFromSubscriptionReceivable		usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2023Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2023Q1	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt		usd
CY2023Q1	TESI	Repayments Of Note Payables Related Parties RepaymentsOfNotePayablesRelatedParties		usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2024Q1	TESI	Settlement Of Note Payable SettlementOfNotePayable		usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount		shares
CY2024Q1	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability		usd
CY2024Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent		usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25386814	shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3427	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	103578	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	36187	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	43016	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	934880	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	218957	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	219919	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	1377183	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6402837	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6461921	usd
CY2024Q1	us-gaap	Goodwill Goodwill	6516915	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	668168	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1480770	usd
CY2024Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	21530611	usd
CY2024Q1	us-gaap	Assets Assets	22907794	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5216118	usd
CY2024Q1	TESI	Customer Deposits CustomerDeposits	523814	usd
CY2023Q4	TESI	Customer Deposits CustomerDeposits	226671	usd
CY2024Q1	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	160608	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	17500	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	397497	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	391547	usd
CY2024Q1	TESI	Shares To Be Issued Current SharesToBeIssuedCurrent	50000	usd
CY2023Q4	TESI	Shares To Be Issued Current SharesToBeIssuedCurrent	50000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	14500906	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12410598	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1199536	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1290866	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4465551	usd
CY2023Q4	us-gaap	Liabilities Liabilities	16876149	usd
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25386814	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25386814	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15134545	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15134545	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	2539	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1513	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	156889062	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	155377798	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-153201282	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-150080049	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	3690382	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	5299325	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22907794	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22175474	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1755750	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1080327	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	1623156	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	1161112	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	132594	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	-80785	usd
CY2024Q1	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	487031	usd
CY2023Q1	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	189316	usd
CY2024Q1	us-gaap	Professional Fees ProfessionalFees	873439	usd
CY2023Q1	us-gaap	Professional Fees ProfessionalFees	194779	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	192867	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6419	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	401640	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	131646	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	1954977	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	522160	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1822383	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-602945	usd
CY2024Q1	TESI	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	17500	usd
CY2024Q1	us-gaap	Interest Expense Other InterestExpenseOther	510454	usd
CY2023Q1	us-gaap	Interest Expense Other InterestExpenseOther	79652	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	56393	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	300	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-436561	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-79352	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2258944	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-682297	usd
CY2024Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	862289	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3121233	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-682297	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	222067042	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	222067042	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	5299325	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	650001	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2258944	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	3690382	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2526104	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2526104	usd
CY2023Q1	TESI	Stock Issued During Period Value Contributions Net Of Distributions StockIssuedDuringPeriodValueContributionsNetOfDistributions	170000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-682297	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	2013807	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	2013807	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2258944	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-682297	usd
CY2024Q1	us-gaap	Provision For Loan Lease And Other Losses ProvisionForLoanLeaseAndOtherLosses	-7207	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	304942	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	119826	usd
CY2024Q1	TESI	Change In Fair Value Of Derivative Liability And Derivative Expense ChangeInFairValueOfDerivativeLiabilityAndDerivativeExpense	17500	usd
CY2024Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	180311	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	4664	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-42956	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-54770	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-29976	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-6876	usd
CY2024Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-7351	usd
CY2023Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	2100	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	74919	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	502500	usd
CY2024Q1	TESI	Increase Decrease In Right Of Use Assets IncreaseDecreaseInRightOfUseAssets	-101854	usd
CY2023Q1	TESI	Increase Decrease In Right Of Use Assets IncreaseDecreaseInRightOfUseAssets	-21594	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1143160	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	81120	usd
CY2024Q1	TESI	Increase Decrease In Deposit IncreaseDecreaseInDeposit	297143	usd
CY2024Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	16282	usd
CY2023Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	21032	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-85380	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-22944	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-822475	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-397459	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	734923	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	50050	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-734923	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-50050	usd
CY2023Q1	TESI	Proceeds From Subscription Receivable ProceedsFromSubscriptionReceivable	200000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	650001	usd
CY2024Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	150000	usd
CY2024Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	50000	usd
CY2024Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	675493	usd
CY2023Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	512470	usd
CY2024Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	328247	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	238848	usd
CY2024Q1	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	290000	usd
CY2024Q1	TESI	Repayments Of Note Payables Related Parties RepaymentsOfNotePayablesRelatedParties	-30000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1457247	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	473622	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-100151	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	26113	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	103578	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	26650	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3427	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	52763	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	172116	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	78770	usd
CY2023Q1	TESI	Settlement Of Note Payable SettlementOfNotePayable	170000	usd
CY2024Q1	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80F_eus-gaap--NatureOfOperations_z1VVksiPPa6g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_82B_zV8K9QQTQOn7">ORGANIZATION AND NATURE OF OPERATIONS</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Titan Environmental Solutions Inc., formerly known as TraQiQ, Inc. (“Titan” or along with its wholly-owned subsidiaries, referred to herein as the “Company”), is engaged in the full-service solution of waste management. Effective January 10, 2024, the Company redomiciled from a California corporation into a Nevada corporation (the “redomicile”). As a result of the redomicile, the Company’s name was changed from TraQiQ, Inc. (“TraQiQ”) to Titan Environmental Solutions Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is based out of Bloomfield Hills, Michigan and offers a comprehensive package of waste reduction, collection, recycling, and technology-enabled solutions to support customer demand. The Company operates two distinct lines of business. The Company’s wholly-owned subsidiary, Titan Trucking, LLC (“Titan Trucking”), is a non-hazardous solid waste management company providing waste and recycling collection and transportation services for industrial generators, commercial contractors and transfer station operators in Michigan. Titan Trucking maintains a fleet of roll off and tractor trailer trucks to perform its services. The Company’s wholly-owned subsidiary Recoup Technologies, Inc. (“Recoup”), provides technology-enabled solutions for food waste processing, including onsite digestors for food waste along with cloud-based software tracking and analytics solutions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 19, 2023, the Company completed its acquisition of Titan Trucking and Titan Trucking’s wholly owned subsidiary, Senior Trucking, LLC (“Senior”). In accordance with ASC 805 - <i>Business Combinations </i>(“ASC 805”), the transaction was treated as a reverse acquisition for financial reporting purposes, with the Company treated as the legal acquirer and Titan Trucking treated as the accounting acquirer. The Company remains the continuing registrant and reporting company. Accordingly, the historical financial and operating data of the Company, which covers periods prior to the closing date of the Titan Merger, reflects the assets, liabilities, and results of operations for Titan Trucking and does not reflect the assets, liabilities and results of operations of the Company for the periods prior to May 19, 2023 (Note 3 – Business Combinations).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 28, 2023, the Company, its wholly-owned subsidiary TraQiQ Solutions, Inc (“Ci2i”), and Ajay Sikka (“Sikka”), a director of the Company and its former chief executive officer, signed an Assignment of Stock Agreement (the “Assignment Agreement”). Under the terms of the Assignment Agreement, the Company assigned and transferred to Sikka all of the rights, title, and interests in the issued and outstanding equity interests of Ci2i in exchange for consideration of $<span id="xdx_902_eus-gaap--BusinessCombinationConsiderationTransferred1_c20230728__20230728__srt--OwnershipAxis__custom--TraqiqSolutionsIncMember__srt--TitleOfIndividualAxis__custom--AjaySikkaMember_z8otE2lPfDS5" title="Consideration exchange">1</span>. The Company additionally assumed from Ci2i loans and short term debts valued at $<span id="xdx_903_eus-gaap--ShortTermBorrowings_iI_c20230728__srt--OwnershipAxis__custom--TraqiqSolutionsIncMember__srt--TitleOfIndividualAxis__custom--AjaySikkaMember_zH2sIzPpmbIf" title="Short term debt">209,587 </span>plus fees and interest. Other than the liabilities assumed from Ci2i, the balance sheet amounts and operations of Ci2i as of the date of sale were insignificant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change in Equity Instruments and Share Authorizations Due to Redomicile</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of the redomicile, each share of TraQiQ’s’s common stock issued and outstanding immediately prior to the redomicile was exchanged for one share of Titan’s common stock. Additionally, each share of the TraQiQ Series C Convertible Preferred Stock issued and outstanding immediately prior to the effective time of the redomicile was exchanged for one share of Series A Convertible Preferred Stock of the Nevada corporation (the “Series A Preferred Stock”), which has substantially the same rights and preferences as the TraQiQ Series C Preferred Stock. Each of TraQiQ’s Series A Rights to Receive Common Stock issued and outstanding immediately prior to the redomicile was exchanged for one Series A Right to Receive Common Stock of Titan, which has substantially the same rights and preferences as the TraQiQ Series A Rights to Acquire Common Stock. Each of the TraQiQ Series B Rights to Receive Common Stock issued and outstanding immediately prior to the redomicile was exchanged for one Series B Right to Receive Common Stock of Titan, which has substantially the same rights and preferences as the TraQiQ Series B Rights to Acquire Common Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of the redomicile, all of TraQiQ’s outstanding warrants were assumed by Titan and now represent warrants to acquire shares of Titan’s common stock. The redomicile increased the Company’s authorized capital stock to <span id="xdx_90B_eus-gaap--CapitalUnitsAuthorized_iI_c20240110_zOrWBkokrTU4" title="Authorized capital total">425,000,000</span> total shares, consisting of <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20240110_zaIe1w7Wyxtc" title="Common stock, shares authorized">400,000,000</span> shares of common stock, par value $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240110_zsa1453HYGTh" title="Common stock, par value">0.0001</span> per share, and <span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20240110_zcCCaBntyLn9" title="Preferred stock, shares authorized">25,000,000</span> shares of “blank check” preferred stock, par value $<span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20240110_zluvgK5lh6a6" title="Preferred stock, par value">0.0001</span> per share, of which <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20240110__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zgfBC2Ai9lvg" title="Preferred stock, shares authorized">630,900</span> shares were designated “Series A Convertible Preferred Stock”. In connection with the redomicile, the Company also adopted the “Titan Environmental Solutions Inc. 2023 Equity Incentive Plan.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going Concern</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s consolidated financial statements as of March 31, 2024 and December 31, 2023 are prepared using accounting principles generally accepted in the United States of America (“GAAP”), which contemplates continuation of the Company as a going concern. This contemplates the realization of assets and liquidation of liabilities in the ordinary course of business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended March 31, 2024, the Company had a net loss of $<span id="xdx_90B_eus-gaap--NetIncomeLoss_iN_di_c20240101__20240331_zIXWJH7YdEN6" title="Net income loss">2,258,944</span>. The working capital of the Company was a deficit of $<span id="xdx_90E_ecustom--WorkingCapitalDeficit_iI_c20240331_zXDYKaFLb2nd" title="Working capital deficit">13,123,723</span> as of March 31, 2024 (deficit of $<span id="xdx_908_ecustom--WorkingCapitalDeficit_iI_c20231231_zpCs8cCdlkDk" title="Working capital deficit">10,935,108</span> as of December 31, 2023). <span style="background-color: white">The March 31, 2024 working capital deficiency includes $<span id="xdx_905_eus-gaap--RepaymentsOfDebt_c20240101__20240331_zvhuZ1cHA6ck" title="Principal repayment of note">2,257,090</span> of principal repayments from the Michaelson Note <span style="background-color: white">(as defined in Note 9 – Notes Payable) </span> due by June 30, 2024; the Company currently does not have sufficient funds to repay this debt. </span>As a result of these factors, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern for a period of one year after the date that the consolidated financial statements are issued. The Company’s consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management’s plans include raising capital through issuances of equity and debt securities, and minimizing operating expenses of the business to improve the Company’s cash burn rate. On July 17, 2023, the Company converted $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20230717_zOcB7gXPCZh7" title="Debt instrument face amount">1,944,000</span> of principal and $<span id="xdx_904_eus-gaap--InterestExpense_c20230717__20230717__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zlmHJrAoHl1h" title="Accrued interest">75,263</span> of accrued interest related to its outstanding convertible note payables into Series A rights to receive common stock (“Series A Rights”), resulting in the extinguishment of almost all of the Company’s convertible note embedded derivative liabilities. In addition, the Company has been successful in attracting substantial capital from investors interested in the current public status of the Company that has been used to support its ongoing cash outlays. This includes $<span id="xdx_90A_eus-gaap--ConvertibleNotesPayable_iI_c20240331_zNNNXWKYU2P5" title="Convertible notes payable">250,000</span> of convertible notes (Note 10 – Convertible Notes Payable) and $<span id="xdx_905_eus-gaap--ConvertibleNotesPayable_iI_c20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSuqe74fNfh" title="Convertible notes">650,000</span> of warrants (Note 14 – Stockholders’ Equity) during the three months ended March 31, 2024 (Note 10 - Convertible Notes Payable). The Company believes, but cannot guarantee, it will continue to be able to attract capital from outside sources as it pursues a move to a national stock exchange. The Company has engaged a qualified investment bank to assist in the uplisting of its common stock and simultaneous raise of capital. In addition, the Company’s revenue continues to grow and management expects the Company to shrink its net losses over the upcoming quarters through organic and acquisitive growth. The Company has identified a plan to decrease expenses going forward to reduce its cash burn.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	425000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2258944	usd
CY2024Q1	TESI	Working Capital Deficit WorkingCapitalDeficit	13123723	usd
CY2023Q4	TESI	Working Capital Deficit WorkingCapitalDeficit	10935108	usd
CY2024Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	2257090	usd
CY2023Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1944000	usd
CY2024Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	250000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84D_eus-gaap--UseOfEstimates_z546ITCHp6Ic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zxdWiqcW3RH9">Accounting Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	36187	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	43016	usd
CY2024Q1	us-gaap	Amortization Of Deferred Loan Origination Fees Net AmortizationOfDeferredLoanOriginationFeesNet	180311	usd
CY2023Q1	us-gaap	Amortization Of Deferred Loan Origination Fees Net AmortizationOfDeferredLoanOriginationFeesNet	4664	usd
CY2024Q1	us-gaap	Notes And Loans Payable NotesAndLoansPayable	318867	usd
CY2023Q4	us-gaap	Notes And Loans Payable NotesAndLoansPayable	434542	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1755750	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1080327	usd
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zZEdcpCDZkf7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zuwCa8E4poy8">Concentration Risk from Revenues</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A major customer is defined as a customer that represents 10% or greater of total revenues. The Company does not believe that the risk associated with these customers or vendors will have an adverse effect on the business. The Company’s concentration of revenue is as follows:</span></p> <p id="xdx_89A_eus-gaap--ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_zzj8C5QvKuDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zPOxC4xquC0i" style="display: none">SCHEDULE OF CONCENTRATION RISK</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Customer A</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerAMember_z611slWK8boj" title="Concentration risk, percentage">15</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerAMember_fKg_____zuvH8pgtTiY4" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0645">-</span></span><span id="xdx_F20_zWqhBD5MP4U7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Customer B</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerBMember_zG3mm3ldsR1f" title="Concentration risk, percentage">20</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerBMember_z2gSCYO1GGJ6" title="Concentration risk, percentage">53</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> Represents amounts less than 10%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="display: none; vertical-align: top; text-align: justify"> <td id="xdx_F04_zCgHgv0hmaDl" style="width: 55pt; text-align: right"></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F16_zEyQNcl8yfY7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents amounts less than 10%</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentration Risk from Accounts Receivable</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A major customer is defined as a customer that represents 10% or greater of total accounts receivable, net. The Company does not believe that the risk associated with these customers or vendors will have an adverse effect on the business. The Company’s concentration of accounts receivable is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As of March 31, 2024</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As of December 31, 2023</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer A</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerAMember_zcPdQlIvfQfd" title="Concentration risk, percentage">15</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerAMember_fKg_____zyG4KlkvTLI9" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0653">-</span></span><span id="xdx_F2E_zvsGolwD5xxg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer B</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerBMember_z1OtPythEeve" title="Concentration risk, percentage">22</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerBMember_zRvkXpDBhxqc" title="Concentration risk, percentage">24</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer C</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerCMember_zl7IHj7LQPJj" title="Concentration risk, percentage">11</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerCMember_fKg_____zS8k7bz81FQe" style="display: none" title="Concentration risk, percentage"><span style="-sec-ix-hidden: xdx2ixbrl0661">-</span></span><span id="xdx_F21_zD0uRjMAEV8a" style="font-size: 10pt"></span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Represents amounts less than 10%</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"></p> <p style="margin-top: 0; margin-bottom: 0"></p> <p style="margin-top: 0; margin-bottom: 0"></p> <table cellpadding="0" cellspacing="0" style="margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="display: none; vertical-align: top; text-align: justify"> <td id="xdx_F02_zm14DpEO7rK1" style="width: 55pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F15_zoQe3GZqTKX1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents amounts less than 10%</span></td> </tr></table> <p id="xdx_8AA_zjwrYyRDzFCf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains positive customer relationships and continually expands its customer base, mitigating the impact of any potential concentration risks that exist.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	68352119	shares
CY2024Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	23399	usd
CY2023Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	1348	usd
CY2023Q1	TESI	Share Based Compensation Pro Forma ShareBasedCompensationProForma	5590485	usd
CY2023Q1	TESI	Goodwill Impairment Loss Pro Forma GoodwillImpairmentLossProForma	20364001	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7970981	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7236057	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1568144	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1455310	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6402837	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5780747	usd
CY2024Q1	us-gaap	Depreciation Depreciation	112834	usd
CY2023Q1	us-gaap	Depreciation Depreciation	112951	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3280982	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	3911446	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3174685	usd
CY2024Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	235421	usd
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	79652	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	697200	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	505091	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6461921	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6654030	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6461921	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6654030	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	192109	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6875	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	580357	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	770356	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	770356	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	770356	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	711930	usd
CY2024Q1	TESI	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	2858566	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6461921	usd
CY2024Q1	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	4363790	usd
CY2023Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	3475570	usd
CY2024Q1	TESI	Credit Card Payable CreditCardPayable	152303	usd
CY2023Q4	TESI	Credit Card Payable CreditCardPayable	153728	usd
CY2024Q1	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	379187	usd
CY2023Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	233611	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	320838	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	210049	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	5216118	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	4072958	usd
CY2024Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P12M
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y7M20D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y10M9D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0810	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0810	pure
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	395270	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	460980	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	485504	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	418442	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	102211	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1862407	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	265374	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1597033	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	397497	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1199536	usd
CY2024Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	136129	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	25304	usd
CY2024Q1	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	4446429	usd
CY2024Q1	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	3332739	usd
CY2023Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	3932831	usd
CY2023Q4	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	3228010	usd
CY2024Q1	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	26847	usd
CY2024Q1	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	51757	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	21385	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	53325	usd
CY2024Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	4419582	usd
CY2024Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	0	usd
CY2023Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	17500	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	17500	usd
CY2024Q1	TESI	Derivative Gain Loss On Derivative DerivativeGainLossOnDerivative	-17500	usd
CY2024Q1	TESI	Advance On Offering Current AdvanceOnOfferingCurrent	50000	usd
CY2023Q4	TESI	Advance On Offering Current AdvanceOnOfferingCurrent	50000	usd
CY2024Q1	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	23000	usd
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	22500	usd
CY2024Q1	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.50	pure
CY2024Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	1	pure
CY2024Q1	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	3129	usd
CY2023Q1	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	2858	usd
CY2024Q1	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	425000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	TESI	Member Equity MemberEquity	2526104	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25386814	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25386814	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15134545	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15134545	shares
CY2024Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	10252269	shares
CY2023Q3	TESI	Unreimbursed Advances UnreimbursedAdvances	100000	usd
CY2023Q4	TESI	Deemed Dividend Consideration Impact DeemedDividendConsiderationImpact	1075000	usd
CY2024Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2750001	shares
CY2023Q1	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	650000	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.55
CY2023Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	862289	usd
CY2023Q3	TESI	Unreimbursed Advances UnreimbursedAdvances	100000	usd
CY2023Q3	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	324000	usd
CY2024Q1	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd
CY2023Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1755750	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1080327	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	132594	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	-80785	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2258944	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-682297	usd
CY2024Q1	us-gaap	Assets Assets	22907794	usd
CY2023Q4	us-gaap	Assets Assets	22175474	usd
CY2024Q1	us-gaap	Segment Expenditure Addition To Long Lived Assets SegmentExpenditureAdditionToLongLivedAssets	734923	usd
CY2023Q1	us-gaap	Segment Expenditure Addition To Long Lived Assets SegmentExpenditureAdditionToLongLivedAssets	50050	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	304942	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	119826	usd

Files In Submission

Name	View Source	Status
0001493152-24-019697-index-headers.html	Edgar Link	pending
0001493152-24-019697-index.html	Edgar Link	pending
0001493152-24-019697.txt	Edgar Link	pending
0001493152-24-019697-xbrl.zip	Edgar Link	pending
ex2-3.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tesi-20240331.xsd	Edgar Link	pending
tesi-20240331_def.xml	Edgar Link	unprocessable
tesi-20240331_pre.xml	Edgar Link	unprocessable
tesi-20240331_cal.xml	Edgar Link	unprocessable
tesi-20240331_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TESI
Titan Environmental Solutions Inc Stock $tesi

2024 Q2 Form 10-Q Financial Statement

#000149315224019697 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TESI Titan Environmental Solutions Inc Stock $tesi

2024 Q2 Form 10-Q Financial Statement

#000149315224019697 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TESI
Titan Environmental Solutions Inc Stock $tesi